A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
As airports grow more complex, the real innovation lies in making their systems simpler, faster, and easier to act on
Updated
April 13, 2026 3:17 PM
An airplane parked at Josep Tarradellas Barcelona-El Prat Airport. PHOTO: UNSPLASH
Airports are some of the most complex systems in the world. Every day, they manage thousands of flights, passengers, crew schedules, gates and ground operations—all moving at the same time. But much of this still runs on older software that doesn’t connect well, making simple decisions harder than they need to be.
This is the gap companies like AirportLabs are trying to address. Instead of relying on multiple disconnected systems, their approach brings airport operations into one cloud-based platform. The goal is straightforward: take scattered data and turn it into something teams can actually use in real time.
In practice, this means combining core systems like flight databases, resource management and display systems into a single interface. When everything is connected, airport staff can respond faster—whether it’s adjusting gate assignments, managing delays, or coordinating ground crews. Rather than reacting late, decisions can be made as situations unfold.
Another shift is how this technology is built. Traditional airport systems often require heavy on-site infrastructure and long deployment timelines. In contrast, cloud-based platforms remove much of that complexity. Updates are faster, systems are easier to scale and teams spend less time maintaining servers and more time improving operations.
What stands out is the speed of adoption. Instead of multi-year rollouts, newer systems can be implemented in weeks, allowing airports to see improvements much sooner.
At a broader level, this reflects a familiar pattern seen across industries. As operations become more data-heavy, the advantage shifts to those who can simplify complexity. In aviation, that doesn’t just mean better technology—it means making the entire system easier to run.